Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial-Reference-Cited by-同舟云学术

Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial

Published:2021-11-22 Issue:1 Volume:9 Page:164-177
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Lund Lars H.¹²,Savarese Gianluigi¹²,Venkateshvaran Ashwin¹²,Benson Lina¹,Lundberg Anna³,Donal Erwan⁴,Daubert Jean‐Claude⁴,Oger Emmanuel⁵,Linde Cecilia¹,Hage Camilla¹²

Affiliation:

1. Cardiology Unit, Department of Medicine Karolinska Institute Stockholm Sweden

2. Heart, Vascular and Neuro Theme, Department of Cardiology, Heart Failure Section Karolinska University Hospital Stockholm SE‐171 64 Sweden

3. Novartis Sverige Kista Sweden

4. University of Rennes, CHU Rennes, Inserm, LTSI—UMR 1099 Rennes France

5. Pharmacologie Clinique et CIC‐IP 1414, CHU Rennes et Université Rennes‐1 Rennes France

Funder

Vetenskapsrådet

Novartis

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.13705

Reference33 articles.

1. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC;McDonagh TA;Eur Heart J,2021

2. Empagliflozin in Heart Failure with a Preserved Ejection Fraction

3. Spironolactone for Heart Failure with Preserved Ejection Fraction

4. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

5. The perindopril in elderly people with chronic heart failure (PEP-CHF) study

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Role of Epicardial Adipose Tissue-Derived Proteins in Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation: A Bioinformatics Analysis;Journal of Inflammation Research;2024-09

2. Heart failure with preserved ejection fraction;Nature Reviews Disease Primers;2024-08-14

3. Global perspectives on heart failure with preserved ejection fraction: Unravelling regional variations in a complex syndrome;European Journal of Heart Failure;2024-07-30

4. Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fraction;ESC Heart Failure;2024-05-16

5. Non-eligibility for pivotal HFpEF/HFmrEF outcome trials and mortality in a contemporary heart failure cohort;European Journal of Internal Medicine;2023-12